According to the latest SNS Insider report, the Nucleotide Market, valued at USD 597.2 million in 2022, is set to achieve unprecedented growth, reaching USD 944.6 million by 2030. Projections indicate a robust Compound Annual Growth Rate (CAGR) of 5.9% over the forecast period from 2023 to 2030.
Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.
SANTA CLARA (dpa-AFX) - Agilent Technologies, Inc. (A) announced Monday an agreement with Quest Diagnostics (DGX), a diagnostic information services company, to enable providers and patients throughout
The US Food and Drug Administration (FDA) has approved Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM (adagrasib). Click to read more.